The impact of mepolizumab on the sputum level of eosinophil-derived protein in three cases of severe asthma

Allergol Int. 2020 Oct;69(4):639-641. doi: 10.1016/j.alit.2020.03.009. Epub 2020 May 19.

Authors

Toshiyuki Koya¹, Yosuke Kimura², Masachika Hayashi², Takashi Hasegawa³, Toshiaki Kikuchi²

Affiliations

¹ Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Electronic address: tkoya@med.niigata-u.ac.jp.
² Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
³ Department of General Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.

PMID: 32439281
DOI: 10.1016/j.alit.2020.03.009

No abstract available

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents / pharmacology
Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / diagnosis
Asthma / drug therapy*
Asthma / metabolism*
Biomarkers
Eosinophils / drug effects*
Eosinophils / metabolism*
Humans
Sputum / metabolism*
Treatment Outcome

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Biomarkers
mepolizumab